{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:58:21Z","timestamp":1787065101751,"version":"build-2736575974"},"reference-count":33,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>\n                    Despite global efforts to tackle resistance in extended-spectrum beta-lactamase (ESBL)-producing isolates via old antibiotics, there are limited data on the efficacy of fosfomycin\u2014an old oral antibiotic\u2014against Enterobacteriaceae in the Middle East. The purpose of this study was to evaluate the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of fosfomycin against urinary ESBL-producing isolates of Enterobacteriaceae. Between 2004 and 2015, 363 isolates of ESBL-producing Enterobacteriaceae were recovered from high-risk patients suffering from cardiac disorders and were subjected to polymerase chain reaction using specific primers for the\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>TEM<\/jats:sub>\n                    ,\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>SHV<\/jats:sub>\n                    , and\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>CTX-M<\/jats:sub>\n                    genes. Antibiotic susceptibility testing was performed for fosfomycin and other antibiotic comparators. For the isolates considered nonsusceptible to fosfomycin by disk diffusion, the minimum inhibitory concentration (MIC) was determined. The susceptibility rate to fosfomycin remained almost steady (90\u2013100%) over a 12-year period, although it fluctuated vis-\u00e0-vis ciprofloxacin (0\u201354%), trimethoprim\/sulfamethoxazole (9.1\u201331.7%), and nitrofurantoin (41.7\u2013100%). Of all the antibiotics tested, fosfomycin was the most active antimicrobial agent (97%) against the ESBL-positive isolates. Fosfomycin maintained higher activity against ESBL-\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    than against ESBL-\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    . Only 11 (3%) isolates were not susceptible to fosfomycin according to disk diffusion and they had MICs greater than 1,024\u2009mg\/ml. All of the fosfomycin-nonsusceptible isolates were positive for the\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>CTX-M<\/jats:sub>\n                    gene (100%), while 5 (45.4%) and 3 (27.3%) of the isolates harbored the\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>TEM<\/jats:sub>\n                    and\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>SHV<\/jats:sub>\n                    genes, respectively. We showed that fosfomycin had a numerically higher susceptibility rate than the other antibiotics against the ESBL-producing isolates of the most common Enterobacteriaceae. Given its low resistance rate and oral administration, fosfomycin may be deemed a promising antibiotic for the treatment of urinary tract infections caused by ESBL-producing Enterobacteriaceae.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2017.0097","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T11:29:51Z","timestamp":1508844591000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years"],"prefix":"10.1177","volume":"24","author":[{"given":"Parisa","family":"Aris","sequence":"first","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Boroumand","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rahbar","sequence":"additional","affiliation":[{"name":"Reference Health Laboratories","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Douraghi","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Iran"]},{"name":"Tehran University of Medical Sciences","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/673453"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1592\/phco.21.11.920.34529","article-title":"Extended\u2010spectrum \u03b2\u2010lactamases: epidemiology, detection, and treatment","volume":"21","author":"Nathisuwan S.","year":"2001","unstructured":"Nathisuwan S., , Burgess D.S., , and Lewis J.S.. 2001. Extended\u2010spectrum \u03b2\u2010lactamases: epidemiology, detection, and treatment. Pharmacotherapy, 21:920\u2013928.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.49.5.2137-2139.2005","article-title":"High levels of antimicrobial coresistance among extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"49","author":"Schwaber M.J.","year":"2005","unstructured":"Schwaber M.J., , Navon-Venezia S., , Schwartz D., , and Carmeli Y.. 2005. High levels of antimicrobial coresistance among extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother., 49:2137\u20132139.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.190"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/604713"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archinte.165.12.1375","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae: variability by site of infection","volume":"165","author":"Hyle E.P.","year":"2005","unstructured":"Hyle E.P., , Lipworth A.D., , Zaoutis T.E., , Nachamkin I., , Bilker W.B., , and Lautenbach E.. 2005. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae: variability by site of infection. Arch. Intern. Med., 165:1375\u20131380.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/319757"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/432940","article-title":"Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy","volume":"41","author":"Ebbing L.","year":"2005","unstructured":"Ebbing L., , Metlay J.P., , Bilker W.B., , Edelstein P.H., , and Fishman N.O.. 2005. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin. Infect. Dis., 41:923\u2013929.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/423844"},{"key":"e_1_3_3_14_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2016. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI Supplement M100S Wayne PA."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00171-08"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/ice.2015.239","article-title":"Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the southeastern united states","volume":"37","author":"Thaden J.T.","year":"2016","unstructured":"Thaden J.T., , Fowler V.G., , Sexton D.J., , and Anderson D.J.. 2016. Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the southeastern united states. Infect. Control Hosp. Epidemiol., 37:49\u201354.","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/jac\/dkt500","article-title":"Proportion of extended-spectrum \u03b2-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence\u2014systematic review","volume":"69","author":"Tansarli G.S.","year":"2014","unstructured":"Tansarli G.S., , Poulikakos P., , Kapaskelis A., , and Falagas M.E.. 2014. Proportion of extended-spectrum \u03b2-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence\u2014systematic review. J. Antimicrob. Chemother., 69:1177\u20131184.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.41.9.2059","article-title":"Adaptive mutations produce resistance to ciprofloxacin","volume":"41","author":"Riesenfeld C.","year":"1997","unstructured":"Riesenfeld C., , Everett M., , Piddock L., , and Hall B.G.. 1997. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob. Agents Chemother., 41:2059\u20132060.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-003-1084-2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.02614-15","article-title":"Activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing uropathogens in patients in the community and hospitalized patients","volume":"60","author":"Linsenmeyer K.","year":"2016","unstructured":"Linsenmeyer K., , Strymish J., , Weir S., , Berg G., , Brecher S., , and Gupta K.. 2016. Activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing uropathogens in patients in the community and hospitalized patients. Antimicrob. Agents Chemother., 60:1134\u20131136.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.50.1.368-370.2006","article-title":"In vitro activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures","volume":"50","author":"de Cueto M.","year":"2006","unstructured":"de Cueto M., , Hern\u00e1ndez J.R., , L\u00f3pez-Cerero L., , Morillo C., , and Pascual A.. 2006. In vitro activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob. Agents Chemother., 50:368\u2013370.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1157\/13095372","article-title":"Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido","volume":"24","author":"de Cueto M.","year":"2006","unstructured":"de Cueto M., , Hern\u00e1ndez J.R., , L\u00f3pez-Cerero L., , Morillo C., , and Pascual \u00c1.. 2006. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido. Enferm. Infecc. Microbiol. Clin., 24:613\u2013616.","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-015-1018-9"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00345-013-1031-5","article-title":"Increasing prevalence of ciprofloxacin resistance in extended-spectrum-\u03b2-lactamase-producing Escherichia coli urinary isolates","volume":"31","author":"Bonkat G.","year":"2013","unstructured":"Bonkat G., , M\u00fcller G., , Braissant O., , Frei R., , Tschudin-Suter S., , Rieken M., , Wyler S., , Gasser T.C., , Bachmann A., , and Widmer A.F.. 2013. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-\u03b2-lactamase-producing Escherichia coli urinary isolates. World J. Urol., 31:1427\u20131432.","journal-title":"World J. Urol."},{"key":"e_1_3_3_25_2","first-page":"914","article-title":"In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria","volume":"24","author":"Khan I.U.","year":"2014","unstructured":"Khan I.U., , Mirza I.A., , Ikram A., , Ali S., , Hussain A., , and Ghafoor T.. 2014. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. J. Coll. Physicians Surg. Pak., 24:914\u2013917.","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000371734","article-title":"Antibacterial activity of fosfomycin against uropathogens","volume":"60","author":"Sun F.","year":"2015","unstructured":"Sun F., , Chen S., , Qiu X., , Sun Y., , Feng W., , Chen J., , and Xia P.. 2015. Antibacterial activity of fosfomycin against uropathogens. Chemotherapy., 60:157\u2013161.","journal-title":"Chemotherapy."},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/j.ijid.2013.04.005","article-title":"Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community-and hospital-acquired urinary tract infections in Turkey","volume":"17","author":"Demir T.","year":"2013","unstructured":"Demir T., , and Buyukguclu T.. 2013. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community-and hospital-acquired urinary tract infections in Turkey. Int. J. Infect. Dis., 17:e966\u2013e970.","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diagmicrobio.2006.11.015","article-title":"In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum \u03b2-lactamase\u2013producing Escherichia coli isolated from urine and blood","volume":"58","author":"Ko K.S.","year":"2007","unstructured":"Ko K.S., , Suh J.Y., , Peck K.R., , Lee M.Y., , Oh W.S., , Kwon K.T., , Sung D.S., , Lee N.Y., , and Song J.-H.. 2007. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum \u03b2-lactamase\u2013producing Escherichia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis., 58:111\u2013115.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu H.-Y.","year":"2011","unstructured":"Liu H.-Y., , Lin H.-C., , Lin Y.-C., , Yu S.-H., , Wu W.-H., , and Lee Y.-J. 2011. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. Microbiol. J. Immunol. Infect. 44:364\u2013368.","journal-title":"Microbiol. J. Immunol. Infect"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4236\/ojmm.2016.63014","article-title":"Activity of fosfomycin in extended-spectrum beta-lactamases producing Klebsiella pneumoniae from Hospital Acquired Urinary Tract Infections","volume":"6","author":"Mashaly G.E.-S.","year":"2016","unstructured":"Mashaly G.E.-S. 2016. Activity of fosfomycin in extended-spectrum beta-lactamases producing Klebsiella pneumoniae from Hospital Acquired Urinary Tract Infections. Open J. Med. Microbiol., 6:104.","journal-title":"Open J. Med. Microbiol."},{"key":"e_1_3_3_31_2","first-page":"125","article-title":"Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum \u03b2-lactamase producing strains","volume":"8","author":"Sefidan F.Y.","year":"2016","unstructured":"Sefidan F.Y., , Ghotaslou R., , Akhi M.T., , Sadeghi M.R., , Asl Y.M., , and Baghi H.B.. 2016. Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum \u03b2-lactamase producing strains. Iranian J. Microbiol., 8:125\u2013131.","journal-title":"Iranian J. Microbiol."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03484-13"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu H.","year":"2007","unstructured":"Pullukcu H., , Tasbakan M., , Sipahi O.R., , Yamazhan T., , Aydemir S., , and Ulusoy S.. 2007. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int. J. Antimicrobial. Agents., 29:62\u201365.","journal-title":"Int. J. Antimicrobial. Agents."},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0924-8579(03)00231-0","article-title":"Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int","volume":"22","author":"Schito G.","year":"2003","unstructured":"Schito G. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrobial. Agents., 22:79\u201383.","journal-title":"J. Antimicrobial. Agents."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2017.0097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:31:50Z","timestamp":1777667510000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2017.0097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1089\/mdr.2017.0097"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2017.0097","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}